Scarica l'app Stockscreener
16.03
2.10%
0.33
Dopo l'orario di chiusura:
16.02
-0.01
-0.06%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché ERAS Giù?
Forum
Previsione
Precedente Chiudi:
$15.70
Aprire:
$15.37
Volume 24 ore:
8.25M
Relative Volume:
1.79
Capitalizzazione di mercato:
$5.61B
Reddito:
-
Utile/perdita netta:
$-277.02M
Rapporto P/E:
-17.18
EPS:
-0.9328
Flusso di cassa netto:
$-91.36M
1 W Prestazione:
-1.41%
1M Prestazione:
-11.53%
6M Prestazione:
+2.89%
1 anno Prestazione:
+934.19%
Intervallo 1D:
$15.37
$17.25
Intervallo di 1 settimana:
$15.37
$17.25
Portata 52W:
$1.53
$24.28
Erasca Inc Stock (ERAS) Company Profile
Nome
Erasca Inc
Settore
Industria
Telefono
(858) 465-6511
Indirizzo
3115 MERRYFIELD ROW, SAN DIEGO
Compare ERAS vs VRTX, REGN, ARGX, MRNA, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ERAS
Erasca Inc
|
16.03 | 5.49B | 0 | -277.02M | -91.36M | -0.9328 |
VRTX
Vertex Pharmaceuticals Inc
|
514.56 | 132.08B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
793.26 | 83.15B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
984.04 | 62.71B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
136.62 | 54.14B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
203.35 | 44.51B | 742.00K | -1.37B | -1.07B | -7.0731 |
Erasca Inc Stock (ERAS) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-01-27 | Ripresa | Mizuho | Outperform |
| 2026-01-07 | Iniziato | Piper Sandler | Overweight |
| 2025-10-16 | Iniziato | Stifel | Buy |
| 2025-09-03 | Downgrade | BofA Securities | Buy → Underperform |
| 2025-08-18 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2025-03-26 | Iniziato | Raymond James | Outperform |
| 2024-11-18 | Iniziato | Jefferies | Buy |
| 2024-03-11 | Iniziato | CapitalOne | Overweight |
| 2024-01-05 | Downgrade | BofA Securities | Buy → Neutral |
| 2023-10-11 | Iniziato | H.C. Wainwright | Buy |
| 2023-03-30 | Iniziato | Mizuho | Buy |
| 2023-02-24 | Iniziato | Goldman | Buy |
| 2023-02-03 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
Mostra tutto
Erasca Inc Borsa (ERAS) Ultime notizie
Attention Long-Term Shareholders of Aardvark Therapeutics, - globenewswire.com
Erasca Announces Multiple Presentations at the Upcoming 38th EORTC-NCI-AACR Symposium - The Manila Times
Important Notice to Long-Term Shareholders of Erasca, Inc. - globenewswire.com
ERAS Stock Slumps Nearly 40% After-Hours: Fine Print In 'Positive' Cancer Trial Reveals Treatment-Related Death - Stocktwits
Erasca stock holds gains as FDA Fast Track boosts cancer pipeline - ad-hoc-news.de
FDA Fast Track Puts Erasca’s (ERAS) Pancreatic Bet Center Stage - Yahoo Finance
Erasca stock gains visibility as FDA fast tracks ERAS-0015 - ad-hoc-news.de
Erasca, Inc. (ERAS) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Attention Long-Term Shareholders of Erasca, Inc. (NASDAQ: - GlobeNewswire
Long-Term Shareholders of Erasca, Inc. (ERAS) Are Encouraged to Contact Johnson Fistel Regarding Potential Claims - globenewswire.com
ERASCA, INC. (NASDAQ: ERAS) SHAREHOLDER INVESTIGATION - GlobeNewswire
Bronstein, Gewirtz & Grossman, LLC Encourages Erasca, Inc. (ERAS) Stockholders to Inquire about Securities Investigation - ACCESS Newswire
Should FDA Fast Track for ERAS-0015’s Pan-RAS Glue Require Action From Erasca (ERAS) Investors? - simplywall.st
Bronstein, Gewirtz & Grossman, LLC Is Investigating Erasca, Inc. (ERAS) And Encourages Stockholders to Connect - ACCESS Newswire
Erasca Receives FDA Fast Track Designation for Pan-RAS Molecular Glue ERAS-0015 in Metastatic Pancreatic Cancer - oncodaily.com
INVESTOR DEADLINE: Erasca, Inc. (ERAS) Investors with Substantial Losses Have Opportunity to Lead the Erasca Class Action Lawsuit - Eastern Progress
Erasca, Inc. (ERAS) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
ERAS Shareholder Alert: Investors With Losses May Seek to Lead the Class Action in Erasca, Inc. Securities LawsuitContact The Gross Law Firm - Eastern Progress
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Erasca, Inc.ERAS - Eastern Progress
Erasca (ERAS) Momentum: Slides 5.67% to $17.05 in the Latest Session; Immediate View: Traders Can Monitor the $16.20-$17.90 Range for the Current SessionIchimoku Kumo Twist - Vinanet
ERAS Stock Slumps Against RVMD Rally — Analyst Stays Bullish - Stocktwits
E Fund Management Co. Ltd. Invests $4.86 Million in Erasca, Inc. $ERAS - MarketBeat
Law firm probes Erasca directors for possible b... - Pluang
ERASCA, INC. (ERAS) SHAREHOLDER INVESTIGATION ALERT: Bernstein Liebhard Investigates Potential Breaches of Fiduciary Duty - TMX Newsfile
81,900 Shares in Erasca, Inc. $ERAS Acquired by Handelsbanken Fonder AB - MarketBeat
Erasca, Inc. (ERAS) Investigation: Bronstein, Gewirtz & Grossman - The National Law Review
Stifel reiterates Buy rating on Erasca stock, $30 target By Investing.com - Investing.com Nigeria
Does Legal Scrutiny And Leadership Change Reshape The Bull Case For Erasca’s ERAS-0015 Program (ERAS)? - Sahm
Stifel reiterates Buy rating on Erasca stock, $30 target - Investing.com
Erasca (NASDAQ: ERAS) foundation to sell 8,333 shares - Stock Titan
ERAS STOCKHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Anno - The National Law Review
Erasca (ERAS) insiders report 10.4% and 5.6% ownership stakes - Stock Titan
ERAS Maintained by B of A Securities -- Price Target Raised to $20 - GuruFocus
Bank of America Issues Positive Forecast for Erasca (NASDAQ:ERAS) Stock Price - MarketBeat
Erasca, Inc. Stock 12‑Month Price Target Raised to $23, Implies 29% Upside - TradingView
Attention Long-Term Shareholders of ARS Pharmaceuticals, - GlobeNewswire
HC Wainwright Has Negative Estimate for Erasca Q3 Earnings - MarketBeat
BofA Adjusts Price Target on Erasca to $20 From $18 - marketscreener.com
Erasca, Inc. (NASDAQ:ERAS) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
Guggenheim raises Erasca stock price target to $21 on pipeline progress - Investing.com Nigeria
Erasca Awards 1.3 Million Stock Options to New President of R&D - Kalkine Media
Erasca, Inc. Stock 12‑Month Price Target Raised to $22.82, Implies 25% Upside - TradingView
Erasca, Inc. Stock 12‑Month Price Target Raised to $22.73, Implies 24% Upside - TradingView
Propanc Biopharma Highlights Differentiated Proenzyme Therapy PRP as a Potential Therapy of Choice Against RAS-Driven Cancers - The Manila Times
Erasca (NASDAQ:ERAS) Given New $22.00 Price Target at HC Wainwright - MarketBeat
H.C. Wainwright raises Erasca stock price target on trial progress By Investing.com - Investing.com South Africa
H.C. Wainwright raises Erasca stock price target on trial progress - Investing.com
ERAS Maintained by HC Wainwright & Co. -- Price Target Raised to $22 - GuruFocus
Bank of America Corp DE Raises Position in Erasca, Inc. $ERAS - MarketBeat
Erasca (NASDAQ:ERAS) Announces Earnings Results, Misses Expectations By $0.03 EPS - MarketBeat
Erasca Q2 EPS of $(0.14) misses $(0.11) estimate on R&D spend - scanx.trade
Erasca Inc Azioni (ERAS) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
3.04%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):